Hematologic Oncology

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.

January 26, 2021 - Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia.

January 25, 2021 - The Japanese Ministry of Health, Labour and Welfare approved the BTK inhibitor acalabrutinib for use in adult patients with relapsed/refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma

Joseph V. Simone, MD, a pioneering clinical investigator and institutional leader in pediatric oncology who was recognized with a 2017 Giants of Cancer Care® award, died January 21 at the age of 85.

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

January 22, 2021 — The Japan Ministry of Health, Labour and Welfare has approved the CAR T-cell therapy axicabtagene ciloleucel for use in the treatment of adult patients with certain relapsed/refractory large B-cell lymphomas.

Expert discuss their expectations for research and drug development in oncology in the new year.

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.